Hinge Health (NYSE: HNGE) reported record third-quarter results on 2 November 2026, with revenue climbing 52% year-on-year to $235.0m from $154.2m a year earlier, according to the company’s SEC filing.
The digital musculoskeletal-care provider also swung to a GAAP operating profit of $50.3m, reversing a $6.1m operating loss in the same quarter last year, and raised full-year revenue guidance to between $879m and $881m, above a FactSet consensus of $860.6m, as first reported by MarketScreener.
A beat-and-raise that barely moved the stock
GAAP diluted earnings per share came in at $0.66, against a loss of $0.02 a share in the third quarter of 2025. Non-GAAP operating income rose 154% to $77.2m, and non-GAAP diluted EPS of $0.71 beat a $0.61 consensus, according to a recap from Chartmill.
Analysts had set a high bar. One estimate tracker put the revenue consensus at $239.03m, slightly above the $235.0m actual figure, per GuruFocus. Shares rose about 1.07% in after-hours trading to $116.72, a muted response given the scale of the margin swing, Investing.com reported. By the close of trading on 2 November the stock stood at $116.91, down 0.35% on the day but up 11.34% over 20 trading days, according to consolidated exchange data.
The quarter extends a sequential run that has lifted revenue from $89.8m in the second quarter of 2024 to $212.8m in the second quarter of 2026, making the $235.0m figure a new high for the company, confirmed against its own SEC filings across multiple quarters.
Billings and client growth underpin the raise
Total clients reached 3,270, up 28% year-on-year, while last-twelve-month calculated billings rose 54% to $960.3m, Chartmill’s recap showed. Hinge Health Co-Founder and CEO Daniel Perez said the quarter reflects the firm’s ability ‘to deliver exceptional clinical outcomes, a better healthcare experience and lower client costs at scale’, according to the company’s release carried on Business Wire.
The turnaround from loss to profit has been building for several quarters. Net income moved from a loss of $575.7m in the second quarter of 2025 – a period that included a large one-off charge – to profits of $35.1m and $43.7m in the first and second quarters of 2026 respectively, based on the company’s 10-Q filings with the SEC.
Context: rates steady, insiders filing
The report landed against a steady but not especially loose rate backdrop. The 10-year US Treasury yield stood at 4.94% on 30 October, down slightly from 4.98% a week earlier, while the unemployment rate edged up to 4.2% in September from 4.1% the prior month, according to data from the Federal Reserve Bank of St Louis. Margin expansion of this scale against that backdrop is unusual for a company of Hinge Health’s size.
FINRA’s daily short-sale data show short-side activity in HNGE climbing to a ratio of 0.56 on 23 October, ahead of the print, falling back below 0.30 by 29 October, then rising again to 0.51 by 2 November – volatile positioning around the result rather than a one-directional move.
Two Form 4 filings landed with the SEC within minutes of each other on 2 November, one from the issuer and one from reporting person James Pursley, both timed around the earnings release, according to EDGAR filings. Neither filing disclosed transaction values at the time of publication.
Hinge Health’s next scheduled disclosure will be its full fourth-quarter 2026 results, when investors will learn whether the raised full-year guidance range of $879m to $881m holds.
This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
